This new pilot program is designed to accelerate the development and review of certain drugs and biological products that are aligned with U.S. national health priorities and to enhance the health interests of Americans.
Similar Posts
FDA-TRACK: Biosimilar User Fee Act Procedural Response Goals Summary
FDA-TRACK: Biosimilar User Fee Act Procedural Response Goals SummaryFDA Responses to Action Items Identified in 2023 Intergovernmental Working Meeting on Drug Compounding
In the most recent Intergovernmental Working Meeting on Drug Compounding, Nov. 7-8, 2023, FDA and state regulators identified three actions items. This page contains a summary of those action items and how FDA has responded.Immacule Lifesciences Private Limited – 09/18/2025
Immacule Lifesciences Private Limited – 09/18/2025. Country: India. Record Type: 483Albertsons Companies Stores in Arkansas, Louisiana, Oklahoma and Texas Voluntarily Recalls Select Items Containing Tuna Salad from Reser’s Fine Foods Due to an Ingredient Recall Linked to Possible Listeria Monocytogenes Contamination
Albertsons, Randalls and Tom Thumb stores in Arkansas, Louisiana, Oklahoma and Texas are voluntarily recalling select items containing tuna salad supplied by Reser’s Fine Foods. This action follows a recall initiated by Reser’s Fine Food due to possible contamination with Listeria monocytogenes in bFDA Information Session on Generic Drug Research Needs & Opportunities for FY 2026 – 01/21/2026
FDA is hosting a virtual Information Session on Generic Drug Research Needs & Opportunities for fiscal year (FY) 2026 on Wednesday, January 21, 2026.Fiscal Year 2024 Generic Drug Science and Research Initiatives Public Workshop – 05/20/2024
The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives.